Kura Oncology (KURA) Stock Forecast & Price Target

Compare

651 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KURA Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Kura

Oncology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KURA Stock 12 Month Forecast

Average Price Target

$23.70

▲(188.32% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $23.70 with a high forecast of $40.00 and a low forecast of $7.95. The average price target represents a 188.32% change from the last price of $8.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","32":"$32","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14,23,32,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.95,10.415384615384616,12.88076923076923,15.346153846153847,17.81153846153846,20.276923076923076,22.74230769230769,25.207692307692305,27.67307692307692,30.138461538461534,32.60384615384615,35.069230769230764,37.534615384615385,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.95,9.161538461538461,10.373076923076923,11.584615384615384,12.796153846153846,14.007692307692308,15.21923076923077,16.43076923076923,17.642307692307693,18.853846153846153,20.065384615384616,21.276923076923076,22.488461538461536,{"y":23.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.95,7.95,7.95,7.95,7.95,7.95,7.95,7.95,7.95,7.95,7.95,7.95,7.95,{"y":7.95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.61,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.19,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$23.70

Lowest Price Target$7.95

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Bradley Canino

Guggenheim

$7.95

Hold

-3.28%

Downside

Initiated

09/03/25

Kura Oncology initiated with a Neutral at GuggenheimKura Oncology initiated with a Neutral at Guggenheim

Charles Zhu

LifeSci Capital

$24

Buy

191.97%

Upside

Reiterated

09/01/25

Optimistic Buy Rating for Kura Oncology: KO-2806's Potential in ccRCC and Market Opportunities

Jonathan Chang

Leerink Partners

$23

Buy

179.81%

Upside

Reiterated

08/21/25

Kura Oncology's KO-2806: A Promising Investment with $1.5 Billion Market Potential in RCC

Mara Goldstein

Mizuho Securities

$30

Buy

264.96%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

David Dai

UBS

$14

Buy

70.32%

Upside

Reiterated

08/12/25

Kura Oncology (KURA) Gets a Buy from UBS

Reni Benjamin

Citizens JMP

$28→$24

Buy

191.97%

Upside

Reiterated

08/11/25

Kura Oncology price target lowered to $24 from $28 at Citizens JMPKura Oncology price target lowered to $24 from $28 at Citizens JMP

Jason Zemansky

Bank of America Securities

$29→$27

Buy

228.47%

Upside

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Globus Medical (NYSE: GMED) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Joseph Pantginis

H.C. Wainwright

$40

Buy

386.62%

Upside

Reiterated

08/08/25

Kura Oncology's Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating

Peter Lawson

Barclays

$11

Buy

33.82%

Upside

Reiterated

08/08/25

Kura Oncology (KURA) Gets a Buy from Barclays

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/07/25

Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating

Justin Zelin

BTIG

―

Hold

―

Reiterated

08/07/25

BTIG Reaffirms Their Hold Rating on Kura Oncology (KURA)We'd be looking for response rates north of 20% in pts failing SOC regimens as a signal of meaningful efficacy with FTI inhibitors across the solid tumors being evaluated.

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

06/26/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)

Robert Driscoll

Wedbush

$36

Buy

337.96%

Upside

Reiterated

06/20/25

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

George Farmer

Scotiabank

$10→$8

Hold

-2.68%

Downside

Reiterated

06/04/25

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

Roger Song

Jefferies

$28

Buy

240.63%

Upside

Reiterated

06/03/25

Kura Oncology's Promising Prospects: Buy Rating Affirmed on Strong KOMET-001 Data and FDA Priority Review

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Bradley Canino

Guggenheim

$7.95

Hold

-3.28%

Downside

Initiated

09/03/25

Kura Oncology initiated with a Neutral at GuggenheimKura Oncology initiated with a Neutral at Guggenheim

Charles Zhu

LifeSci Capital

$24

Buy

191.97%

Upside

Reiterated

09/01/25

Optimistic Buy Rating for Kura Oncology: KO-2806's Potential in ccRCC and Market Opportunities

Jonathan Chang

Leerink Partners

$23

Buy

179.81%

Upside

Reiterated

08/21/25

Kura Oncology's KO-2806: A Promising Investment with $1.5 Billion Market Potential in RCC

Mara Goldstein

Mizuho Securities

$30

Buy

264.96%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

David Dai

UBS

$14

Buy

70.32%

Upside

Reiterated

08/12/25

Kura Oncology (KURA) Gets a Buy from UBS

Reni Benjamin

Citizens JMP

$28→$24

Buy

191.97%

Upside

Reiterated

08/11/25

Kura Oncology price target lowered to $24 from $28 at Citizens JMPKura Oncology price target lowered to $24 from $28 at Citizens JMP

Jason Zemansky

Bank of America Securities

$29→$27

Buy

228.47%

Upside

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Globus Medical (NYSE: GMED) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Joseph Pantginis

H.C. Wainwright

$40

Buy

386.62%

Upside

Reiterated

08/08/25

Kura Oncology's Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating

Peter Lawson

Barclays

$11

Buy

33.82%

Upside

Reiterated

08/08/25

Kura Oncology (KURA) Gets a Buy from Barclays

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/07/25

Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating

Justin Zelin

BTIG

―

Hold

―

Reiterated

08/07/25

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

06/26/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)

Robert Driscoll

Wedbush

$36

Buy

337.96%

Upside

Reiterated

06/20/25

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

George Farmer

Scotiabank

$10→$8

Hold

-2.68%

Downside

Reiterated

06/04/25

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

Roger Song

Jefferies

$28

Buy

240.63%

Upside

Reiterated

06/03/25

Kura Oncology's Promising Prospects: Buy Rating Affirmed on Strong KOMET-001 Data and FDA Priority Review

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kura Oncology

1 Month

xxx

Success Rate

13/20 ratings generated profit

Average Return

+2.07%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +2.07% per trade.

3 Months

xxx

Success Rate

25/43 ratings generated profit

Average Return

+10.92%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.14% of your transactions generating a profit, with an average return of +10.92% per trade.

1 Year

Robert DriscollWedbush

Success Rate

9/18 ratings generated profit

Average Return

+20.54%

reiterated a buy rating 3 months ago

Copying Robert Driscoll's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +20.54% per trade.

2 Years

xxx

Success Rate

22/43 ratings generated profit

Average Return

+23.78%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 51.16% of your transactions generating a profit, with an average return of +23.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KURA Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KURA has received 30 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. KURA average Analyst price target in the past 3 months is 23.70.

Each month's total comprises the sum of three months' worth of ratings.

KURA Financial Forecast

KURA Earnings Forecast

Next quarter’s earnings estimate for KURA is -$0.75 with a range of -$0.99 to $0.49. The previous quarter’s EPS was -$0.75. KURA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year KURA has Outperformed its overall industry.

KURA Sales Forecast

Next quarter’s sales forecast for KURA is $18.94M with a range of $0.00 to $148.40M. The previous quarter’s sales results were $15.29M. KURA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year KURA has Outperformed its overall industry.

KURA Stock Forecast FAQ

What is KURA’s average 12-month price target, according to analysts?

Based on analyst ratings, Kura Oncology’s 12-month average price target is 23.70.

What is KURA’s upside potential, based on the analysts’ average price target?

Kura Oncology has 188.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KURA a Buy, Sell or Hold?

Kura Oncology has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Kura Oncology’s price target?

The average price target for Kura Oncology is 23.70. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $7.95. The average price target represents 188.32% Increase from the current price of $8.22.

What do analysts say about Kura Oncology?

Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of KURA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Kura Oncology (KURA) Stock Forecast & Price Target

KURA Analyst Ratings

KURA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kura Oncology

KURA Analyst Recommendation Trends

KURA Financial Forecast

KURA Earnings Forecast

KURA Sales Forecast

KURA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts